# Elanco Animal Health Inc (ELAN)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/elanco-animal-health-inc/ JSON: https://steadybase.io/company/elanco-animal-health-inc.json Checked Nov 10, 2026. Latest filing read: Nov 6, 2026.

## Company

- Legal name: Elanco Animal Health Inc
- Ticker: ELAN (NYSE)
- SEC CIK: 0001739104
- Industry: Pharmaceutical Preparations (SIC 2834)
- Headquarters: Indianapolis, IN
- Fiscal year ends: December 31
- SEC filer category: Large accelerated filer
- Website: elanco.com
- LinkedIn: https://www.linkedin.com/company/elanco
- Next earnings date: Nov 6, 2026

## Key facts

- Revenue: $4.7B for the fiscal year ended Dec 31, 2025 (10-K filed Feb 24, 2026). Source: https://www.sec.gov/Archives/edgar/data/1739104/000173910426000012/0001739104-26-000012-index.html
- Net income: -$232.0M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 24, 2026). Source: https://www.sec.gov/Archives/edgar/data/1739104/000173910426000012/0001739104-26-000012-index.html
- SG&A: $1.4B for the fiscal year ended Dec 31, 2025 (10-K filed Feb 24, 2026). Source: https://www.sec.gov/Archives/edgar/data/1739104/000173910426000012/0001739104-26-000012-index.html
- Employees: 1,000 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1739104/000173910426000012/elan-20251231.htm
- Shares outstanding: 499,827,067 as of Nov 4, 2026 (10-Q filed Nov 6, 2026). Source: https://www.sec.gov/Archives/edgar/data/1739104/000173910426000057/0001739104-26-000057-index.html
- Auditor: Ernst & Young LLP, Indianapolis, Indiana, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1739104/000173910426000012/elan-20251231.htm

## Business

Elanco Animal Health Incorporated and its subsidiaries (collectively, Elanco, the Company, we, us, or our) is a global leader in animal health, dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets. We partner with farmers, pet owners, veterinarians and society to create value and help our customers improve the health of animals in their care, while also making a meaningful impact on the communities we serve.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1739104/000173910426000012/elan-20251231.htm

## Annual results

| Fiscal year ended | Revenue | Net income | SG&A |
|---|---|---|---|
| Dec 31, 2025 | $4.7B | -$232.0M | $1.4B |
| Dec 31, 2024 | $4.4B | $338.0M | $1.3B |
| Dec 31, 2023 | $4.4B | -$1.2B | $1.3B |
| Dec 31, 2022 | $4.4B | -$78.0M | $1.3B |
| Dec 31, 2021 | $4.8B | -$483.0M | $1.4B |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/elanco-animal-health-inc.json

## Officers and directors

- Jeffrey N. Simmons, PRESIDENT, CEO AND DIRECTOR. LinkedIn: https://linkedin.com/in/jeffsimmons2050. Source: Form 4 filed Sep 22, 2026, https://www.sec.gov/Archives/edgar/data/1739104/000147907926000043/0001479079-26-000043-index.htm
- Robert M. VanHimbergen, EVP and CFO. LinkedIn: https://linkedin.com/in/bob-vanhimbergen-elanco. Source: Form 4 filed Sep 22, 2026, https://www.sec.gov/Archives/edgar/data/1739104/000172416926000043/0001724169-26-000043-index.htm
- Bob VanHimbergen, Executive Vice President and CFO of Elanco Animal Health. Source: 8-K filed Aug 5, 2026, https://www.sec.gov/Archives/edgar/data/1739104/000173910426000040/elanco-20260630exhibit991.htm
- Jamie Preston, EVP, Chief People Officer. Source: Form 3 filed Nov 3, 2026, https://www.sec.gov/Archives/edgar/data/1739104/000216277726000002/0002162777-26-000002-index.htm
- Grace McArdle, EVP, MANUFACTURING AND QUALITY. LinkedIn: https://linkedin.com/in/grace-mcardle-92593b4b. Source: Form 4 filed Mar 5, 2026, https://www.sec.gov/Archives/edgar/data/1739104/000198257326000004/0001982573-26-000004-index.htm
- James M. Meer, CHIEF ACCOUNTING OFFICER. Source: Form 4 filed Mar 5, 2026, https://www.sec.gov/Archives/edgar/data/1739104/000175424326000004/0001754243-26-000004-index.htm
- Lawrence E. Kurzius, Chairman of the Board. Source: 10-K filed Feb 24, 2026, https://www.sec.gov/Archives/edgar/data/1739104/000173910426000012/elan-20251231.htm
- Shiv O'Neill, GC AND CORP SEC. Source: Form 4 filed Aug 18, 2026, https://www.sec.gov/Archives/edgar/data/1739104/000200117126000006/0002001171-26-000006-index.htm
- Art A. Garcia, Director. Source: 10-K filed Feb 24, 2026, https://www.sec.gov/Archives/edgar/data/1739104/000173910426000012/elan-20251231.htm
- Deborah T. Kochevar Ph.D., DVM, Director. Source: 10-K filed Feb 24, 2026, https://www.sec.gov/Archives/edgar/data/1739104/000173910426000012/elan-20251231.htm
- Denise Scots-Knight Ph.D., Director. Source: 10-K filed Feb 24, 2026, https://www.sec.gov/Archives/edgar/data/1739104/000173910426000012/elan-20251231.htm
- Kapila Kapur Anand, Director. Source: 10-K filed Feb 24, 2026, https://www.sec.gov/Archives/edgar/data/1739104/000173910426000012/elan-20251231.htm
- Kirk McDonald, Director. Source: 10-K filed Feb 24, 2026, https://www.sec.gov/Archives/edgar/data/1739104/000173910426000012/elan-20251231.htm
- Michael J. Harrington, Director. Source: 10-K filed Feb 24, 2026, https://www.sec.gov/Archives/edgar/data/1739104/000173910426000012/elan-20251231.htm
- Paul Herendeen, Director. Source: 10-K filed Feb 24, 2026, https://www.sec.gov/Archives/edgar/data/1739104/000173910426000012/elan-20251231.htm
- R. David Hoover, Director. Source: 10-K filed Feb 24, 2026, https://www.sec.gov/Archives/edgar/data/1739104/000173910426000012/elan-20251231.htm
- Stacey Ma Ph.D., Director. Source: 10-K filed Feb 24, 2026, https://www.sec.gov/Archives/edgar/data/1739104/000173910426000012/elan-20251231.htm
- Art Garcia, Board member (per proxy). Source: DEF 14A filed Apr 8, 2026, https://www.sec.gov/Archives/edgar/data/1739104/000173910426000016/elan-20260407.htm
- David Kinard, Named in proxy. Source: DEF 14A filed Apr 8, 2026, https://www.sec.gov/Archives/edgar/data/1739104/000173910426000016/elan-20260407.htm
- James Meer, Named in proxy. Source: DEF 14A filed Apr 8, 2026, https://www.sec.gov/Archives/edgar/data/1739104/000173910426000016/elan-20260407.htm
- José Manuel Correia de Simas, Ph.D., Named in proxy. Source: DEF 14A filed Apr 8, 2026, https://www.sec.gov/Archives/edgar/data/1739104/000173910426000016/elan-20260407.htm
- Kapila Anand, Board member (per proxy). Source: DEF 14A filed Apr 8, 2026, https://www.sec.gov/Archives/edgar/data/1739104/000173910426000016/elan-20260407.htm
- Michael Harrington, Board member (per proxy). Source: DEF 14A filed Apr 8, 2026, https://www.sec.gov/Archives/edgar/data/1739104/000173910426000016/elan-20260407.htm
- Rajeev (Bobby) Modi, Named in proxy. Source: DEF 14A filed Apr 8, 2026, https://www.sec.gov/Archives/edgar/data/1739104/000173910426000016/elan-20260407.htm
- Robert VanHimbergen, Executive Vice President and Chief Financial Officer. Source: DEF 14A filed Apr 8, 2026, https://www.sec.gov/Archives/edgar/data/1739104/000173910426000016/elan-20260407.htm

## Recent 8-K events

- Nov 6, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1739104/000173910426000054/elan-20261106.htm
- Aug 5, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1739104/000173910426000040/elan-20260805.htm
- May 27, 2026: Item 5.07, Submission of matters to a vote of security holders. Source: https://www.sec.gov/Archives/edgar/data/1739104/000110465926067002/tm2615566d1_8k.htm
- May 6, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1739104/000173910426000027/elan-20260506.htm
- Feb 24, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1739104/000173910426000008/elan-20260224.htm
- Jan 12, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1739104/000110465926002723/tm262899d1_8k.htm
- Dec 9, 2025: Item 2.05, Costs associated with exit or disposal activities (restructuring); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1739104/000110465925119486/tm2533048d1_8k.htm
- Nov 5, 2025: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1739104/000173910425000068/elan-20251105.htm
- Nov 3, 2025: Item 1.01, Entry into a material definitive agreement; Item 2.03, Creation of a direct financial obligation; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1739104/000110465925105246/tm2529998d1_8k.htm
- Aug 7, 2025: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1739104/000173910425000052/elan-20250807.htm

## Insider trades (Form 4)

- Oct 15, 2026: Timothy J. Bettington (SEE REMARKS) sold 4,350 shares, about $100,050. Source: https://www.sec.gov/Archives/edgar/data/1739104/000179789426000006/0001797894-26-000006-index.htm
- Aug 20, 2026: Lawrence Erik Kurzius (Director) bought 40,000 shares, about $936,000. Source: https://www.sec.gov/Archives/edgar/data/1739104/000135209026000006/0001352090-26-000006-index.htm
- Aug 18, 2026: Shiv O'Neill (GC AND CORP SEC) bought 3,998 shares, about $94,273. Source: https://www.sec.gov/Archives/edgar/data/1739104/000200117126000006/0002001171-26-000006-index.htm
- Aug 12, 2026: Michael J. Harrington (Director) bought 5,000 shares, about $109,100. Source: https://www.sec.gov/Archives/edgar/data/1739104/000156634026000006/0001566340-26-000006-index.htm
- Aug 7, 2026: Robert M. VanHimbergen (EVP and CFO) bought 4,200 shares, about $96,936. Source: https://www.sec.gov/Archives/edgar/data/1739104/000172416926000037/0001724169-26-000037-index.htm
- Aug 7, 2026: Paul Herendeen (Director) bought 10,000 shares, about $236,900. Source: https://www.sec.gov/Archives/edgar/data/1739104/000137417526000005/0001374175-26-000005-index.htm
- May 15, 2026: Rajeev A. Modi (SEE REMARKS) bought 4,911 shares, about $99,939. Source: https://www.sec.gov/Archives/edgar/data/1739104/000191647326000024/0001916473-26-000024-index.htm
- May 15, 2026: Jeffrey N. Simmons (PRESIDENT, CEO AND DIRECTOR) bought 4,971 shares, about $99,867. Source: https://www.sec.gov/Archives/edgar/data/1739104/000147907926000025/0001479079-26-000025-index.htm
- Dec 12, 2025: Lawrence Erik Kurzius (Director) bought 10,000 shares, about $213,000. Source: https://www.sec.gov/Archives/edgar/data/1739104/000135209025000011/0001352090-25-000011-index.htm
- Dec 11, 2025: Rajeev A. Modi (SEE REMARKS) bought 4,500 shares, about $95,985. Source: https://www.sec.gov/Archives/edgar/data/1739104/000191647325000017/0001916473-25-000017-index.htm
- Dec 11, 2025: Robert M. VanHimbergen (EVP and CFO) bought 6,950 shares, about $150,398. Source: https://www.sec.gov/Archives/edgar/data/1739104/000172416925000007/0001724169-25-000007-index.htm
- Dec 11, 2025: Jeffrey N. Simmons (PRESIDENT, CEO AND DIRECTOR) bought 22,000 shares, about $478,500. Source: https://www.sec.gov/Archives/edgar/data/1739104/000147907925000017/0001479079-25-000017-index.htm

## What management said

- "Elanco achieved significant adjusted gross margin expansion in the third quarter, up 300 basis points reflecting accelerating price gains to 4% year-over-year and beneficial mix, as well as early progress on our Elanco Ascend productivity initiatives" Bob VanHimbergen, Executive Vice President and CFO of Elanco Animal Health (8-K filed Nov 6, 2026). Source: https://www.sec.gov/Archives/edgar/data/1739104/000173910426000054/elanco-20260930exhibit991.htm
- "Our strong second quarter performance allows us to both raise our full-year outlook and continue to invest in our innovation products, driving market share gains while expanding the total animal health industry" Bob VanHimbergen, Executive Vice President and CFO of Elanco Animal Health (8-K filed Aug 5, 2026). Source: https://www.sec.gov/Archives/edgar/data/1739104/000173910426000040/elanco-20260630exhibit991.htm

## Latest filings

- 8-K filed Aug 5, 2026: https://www.sec.gov/Archives/edgar/data/1739104/000173910426000040/elan-20260805.htm
- 10-K filed Feb 24, 2026: https://www.sec.gov/Archives/edgar/data/1739104/000173910426000012/elan-20251231.htm
- 10-Q filed Aug 5, 2026: https://www.sec.gov/Archives/edgar/data/1739104/000173910426000043/elan-20260630.htm
- DEF 14A filed Apr 8, 2026: https://www.sec.gov/Archives/edgar/data/1739104/000173910426000016/elan-20260407.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/